Prognostic Impact of ANX7-GTPase in Metastatic and HER2-Negative Breast Cancer Patients

Meera Srivastava*, Lukas Bubendorf, Mark Raffeld, Christoph Bucher, Jochen Torhorst, Guido Sauter, Cara Olsen, Olli P. Kallioniemi, Ofer Eidelman, Harvey B. Pollard

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

44 Scopus citations


Purpose: ANX7-GTPase located on chromosome 10q21 is significantly altered and associated with hormone-refractory metastatic prostate cancers. Therefore, we investigated whether levels of ANX7 correlate with breast cancer progression and survival Experimental Design: A diagnostic tumor tissue microarray containing 525 human breast tissue specimens at different stages of the disease was assayed for ANX7 using immunocytochemical methods with ANX7 monoclonal antibody. A separate prognostic tumor tissue microarray containing 553 human breast tissue specimens annotated with clinicopathological parameters was assayed for ANX7, HER2, estrogen receptor, progesterone receptor, and p53 protein. Results: We report here for the first time that the expression of ANX7-GTPase is significantly enhanced and associated with the presence of metastatic disease (P < 0.0001) in the 525 human breast tissue specimens analyzed. Furthermore, using a separate 553 case retrospective prognostic tumor tissue microarray, we found that increased ANX7 expression is also significantly associated with poor overall patient survival (P < 0.014). This is particularly true when restricted to patients in whom the BRE clinical grade is 2 (P < 0.001) or for whom there is a lack of HER2 expression (P < 0.002). Finally, Cox regression analysis shows that as the expression of ANX7 rises, the probability of survival decreases by more than 10-fold for those patients with HER2-negative tumors. These latter patients represented 66% of the population affected with breast cancer in this study. Conclusions: High levels of ANX7 in tumor correlate strongly with poor survival of HER2-negative patients and the most aggressive forms of breast cancer. This is the first study to demonstrate that ANX7 antibody has the potential for development into an in vivo diagnostic and therapeutic tool. This simple and reliable immunohistochemical assay may therefore become an important biomarker for metastatic breast cancer diagnosis and management of HER2-negative breast tumor patients.

Original languageEnglish
Pages (from-to)2344-2350
Number of pages7
JournalClinical Cancer Research
Issue number7
StatePublished - 1 Apr 2004
Externally publishedYes


Dive into the research topics of 'Prognostic Impact of ANX7-GTPase in Metastatic and HER2-Negative Breast Cancer Patients'. Together they form a unique fingerprint.

Cite this